<div id="readability-page-1">11:43 AM EDT, 05/13/2026 (MT Newswires) -- Legend Biotech ( LEGN ) reported a solid Q1 for Carvykti, while focus is increasingly shifting to in vivo pipeline programs with potential updates expected in the coming months and additional clinical progress through 2026, RBC Capital Markets said.The brokerage said in a note Tuesday that it was a &#34;strong&#34; quarter for Carvykti with 21% excluding-US and 8% US quarter-over-quarter growth to $597 million, driven by increasing use in earlier lines of therapy, expansion into community treatment centers, and limited competitive pressure.Investor focus is shifting to in vivo CAR-T programs, with the pipeline now including at least three assets targeting GPRC5D, BCMA, and CD19/CD20. The CD19/CD20 program is of particular interest, with an update expected around mid-2026 at a key medical meeting, and given that no abstract was included in the general release, it could potentially be presented as a late breaker in June, the analyst said.&#34;We see Carvykti as a best-in-class CAR-T therapy for multiple myeloma,&#34; the analyst said, adding that the therapy could reach $2.75 billion in 2026 sales and $8 billion at peak sales.The investment firm sees Legend Biotech ( LEGN ) on track toward adjusted company-wide profitability in 2026.RBC raised Legend Biotech's ( LEGN ) price target from $62 to $64, with an outperform rating.Price: 28.78, Change: +0.52, Percent Change: +1.84 MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.</div>

傳奇生物

2 倍做多納斯達克生物技術 ETF - ProShares

IBBQ

傳奇生物報告了 Carvykti 在第一季度的強勁表現，銷售額達到 5.97 億美元，主要得益於治療線使用的增加和治療中心的擴展。RBC 資本市場強調了對體內 CAR-T 項目的關注轉變，特別是 CD19/CD20 資產，預計將在 2026 年中期發佈更新。該公司將傳奇生物的目標股價從 62 美元上調至 64 美元，維持 “跑贏大盤” 的評級，並預計到 2026 年實現調整後的盈利能力。預計 Carvykti 在 2026 年的銷售額將達到 27.5 億美元，峯值銷售額將達到 80 億美元

Legend Biotech Q1 Solid for Carvykti, Focus Shifts to In Vivo Pipeline, RBC Says

fidelity

Invesco Nasdaq Biotechnology ETF

美國制藥 ETF - iShares

基因改革 ETF - ARK

納斯達克生物科技指數 ETF - iShares Nasdaq

醫療業 ETF - SPDR

動態生物技術與基因組 ETF - Invesco

標普生物技術 3 倍做多 - Direxion

標普生物技術 ETF - SPDR

生物科技 ETF - VanEck Vectors

紐交所高增長板生物技術指數 ETF - First Trust

醫藥突破 ETF - ALPS

標普全球醫療股指數 ETF - iShares

醫療業 ETF - Vanguard

加拿大皇家銀行

RBC 表示，傳奇生物第一季度 Carvykti 表現穩健，關注點已轉向體內研發管線